Flexion CEO: Setting Zilretta up to succeed with a history lesson
Locally acting therapies are like a religion to Flexion Therapeutics (NSDQ:FLXN) co-founder & CEO Dr. Mike Clayman, who spent decades at Eli Lilly (NYSE:LLY) with the company’s co-founder, Dr. Neil Bodick, watching promising compounds fail in late-stage trials on the heels of unanticipated safety results.
“That’s part of the reason, not the whole reason but part of the reason, why the industry only has a 60% success rate in Phase III, because you can’t predict what safety’s going to look like if you’re giving a systemically-administered product that has the potential for off-target effects,” Clayman t...
Source: Mass Device - December 1, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Orthopedics Pain Management Pharmaceuticals Wall Street Beat Eli Lilly & Co. Flexion Therapeutics Genzyme Corp. Source Type: news
Zilretta (Triamcinolone Acetonide Extended-Release Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 20, 2017 Category: Drugs & Pharmacology Source Type: news
FDA OKs First Extended-Release Corticosteroid Shot for Knee OA FDA OKs First Extended-Release Corticosteroid Shot for Knee OA
Triamcinolone acetonide extended-release injectable suspension (Zilretta) is a nonopioid option that provides knee OA pain relief over 12 weeks.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 6, 2017 Category: Universities & Medical Training Tags: Rheumatology News Alert Source Type: news
Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain
BURLINGTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 6, 2017 Category: Drugs & Pharmacology Source Type: news
Triamcinolone Acetonide Cream (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 13, 2017 Category: Drugs & Pharmacology Source Type: news
Triesence (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 17, 2017 Category: Drugs & Pharmacology Source Type: news
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog(R) II Cream
DUBLIN, Aug. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referenci... Biopharmaceuticals, Generics, FDA Perrigo, Mycolog, nystatin, triamcinolone acetonide, candidiasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 16, 2017 Category: Pharmaceuticals Source Type: news
Triamcinolone'Slurry' Comparable to Other Steroids for DME
(MedPage Today) -- Homemade tx cost $29 for multiple injections over several years (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 14, 2017 Category: Cardiology Source Type: news
FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye
The FDA issued a safety alert after serious adverse events were reported in at least 43 patients who received a compounded triamcinolone and moxifloxacin product by intravitreal injection.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
Clearside Biomedical launches Phase II diabetic macular edema trial
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the first patient in a Phase II clinical trial of CLS-TA in patients with diabetic macular edema.
The trial plans to evaluate Clearside’s suspension formulation of a corticosteroid, triamcinolone acetonide, as a suprachoroidal injection in combination with an intravitreal injection of Eylea, an anti-VEGF agent.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical launches Phase II diabetic macular edema trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news
Clearside Biomedical highlights interim data from retreatment trial
Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration.
Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical highlights interim data from retreatment trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Clearside Biomedical Source Type: news
Allernaze (Triamcinolone Acetonide Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 2, 2017 Category: Drugs & Pharmacology Source Type: news
IA triamcinolone for knee OA: better QOL at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2017 Category: Drugs & Pharmacology Source Type: news
Intra-articular triamcinolone may be less effective than placebo for certain patients with knee OA
Findings from a study published in the May 16 issue of The Journal of the American Medical Association suggest that triamcinolone injection may be less effective than placebo for treatment of symptomatic knee osteoarthritis (OA). (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - May 20, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news
